The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination
Abstract
Toward a General Flu Vaccination: Current seasonal influenza virus vaccines are targeted against specific viral strains and do not provide broad, durable protection. Seasonal influenza vaccines induce protective antibody responses against regions of viral hemagglutinin (HA) that rapidly mutate so that very soon, the virus becomes resistant to vaccination. Conserved regions of HA also exist, and a major goal of influenza vaccine development is to design a vaccine that elicits antibodies against the conserved regions so that protection against a wide range of viral strains is achieved. Wei et al. (p. 1060 , published online 15 July; see the Perspective by Doms ) show that a combined HA DNA prime, followed by boosting with a seasonal vaccine, elicits broadly cross-reactive neutralizing antibody responses in mice, ferrets, and nonhuman primates, which were protective in mice and ferrets against heterologous influenza challenge. The neutralizing antibodies were directed against the conserved HA stem region, which indicates the possibility that a more broadly protective vaccine against influenza could be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326
Sui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L.-M., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1566 · Cited by 1,130
Okuno, Y., Isegawa, Y., Sasao, F., & Ueda, S. (1993) · Journal of Virology · doi:10.1128/jvi.67.5.2552-2558.1993 · Cited by 489
Corti, D., Suguitan, A. L., Pinna, D., Silacci, C., Fernandez-Rodriguez, B. M., Vanzetta, F., Santos, C., Luke, C. J., Torres-Velez, F. J., Temperton, N. J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41902 · Cited by 437
Khurana, S., Chearwae, W., Castellino, F., Manischewitz, J., King, L. R., Honorkiewicz, A., Rock, M. T., Edwards, K. M., Del Giudice, G., Rappuoli, R., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000624 · Cited by 268
Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity
Yang, Z.-Y., Wei, C.-J., Kong, W.-P., Wu, L., Xu, L., Smith, D. F., & Nabel, G. J. (2007) · Science · doi:10.1126/science.1135165 · Cited by 253
Self-citationKashyap, A. K., Steel, J., Oner, A. F., Dillon, M. A., Swale, R. E., Wall, K. M., Perry, K. J., Faynboym, A., Ilhan, M., Horowitz, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801367105 · Cited by 252
Wei, C.-J., Boyington, J. C., Dai, K., Houser, K. V., Pearce, M. B., Kong, W.-P., Yang, Z.-Y., Tumpey, T. M., & Nabel, G. J. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000799 · Cited by 232
Self-citationThe Rational Design of an AIDS Vaccine
Douek, D. C., Kwong, P. D., & Nabel, G. J. (2006) · Cell · doi:10.1016/j.cell.2006.02.005 · Cited by 166
Self-citationKoup, R. A., Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M., Larkin, B. D., Enama, M. E., Ledgerwood, J. E., Bailer, R. T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009015 · Cited by 133
Self-citation
Cited by
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 885
Self-citationHighly Conserved Protective Epitopes on Influenza B Viruses
Dreyfus, C., Laursen, N. S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D. C., Lee, J. H., Metlagel, Z., Bujny, M. V., Jongeneelen, M., et al. (2012) · Science · doi:10.1126/science.1222908 · Cited by 866
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 822
Wrammert, J., Koutsonanos, D., Li, G.-M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W. I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101352 · Cited by 777
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 699
Self-citationLee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
“This cytotoxic T-cell response is far more efficient in destroying virus-infected cells, intracellular pathogens, and cancerous cells e while also expanding protective immunity against strains of similar pathogens that express homologous epitopes.(196) In the early 2000s, Merck began manufacturing a mixedvalent vaccin…”
BackgroundAdvances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
Cross-neutralization of influenza A viruses mediated by a single antibody loop
Ekiert, D. C., Kashyap, A. K., Steel, J., Rubrum, A., Bhabha, G., Khayat, R., Lee, J. H., Dillon, M. A., O’Neil, R. E., Faynboym, A. M., et al. (2012) · Nature · doi:10.1038/nature11414 · Cited by 481
Krammer, F., Pica, N., Hai, R., Margine, I., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.00641-13 · Cited by 423
Burton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1225416 · Cited by 415
Continuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Influenza Vaccines for the Future
Lambert, L. C., & Fauci, A. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1002842 · Cited by 389
Next-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
Self-citationInfluenza virus hemagglutinin stalk-based antibodies and vaccines
Krammer, F., & Palese, P. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.07.007 · Cited by 326
Current and next generation influenza vaccines: Formulation and production strategies
Soema, P. C., Kompier, R., Amorij, J.-P., & Kersten, G. F. A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.023 · Cited by 314
(2013) · PubMed · Cited by 308
Quadrivalent influenza nanoparticle vaccines induce broad protection
Boyoglu-Barnum, S., Ellis, D., Gillespie, R. A., Hutchinson, G. B., Park, Y.-J., Moin, S. M., Acton, O. J., Ravichandran, R., Murphy, M., Pettie, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03365-x · Cited by 304
Wang, T. T., Tan, G. S., Hai, R., Pica, N., Ngai, L., Ekiert, D. C., Wilson, I. A., García-Sastre, A., Moran, T. M., & Palese, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013387107 · Cited by 302
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
Kanekiyo, M., Joyce, M. G., Gillespie, R. A., Gallagher, J. R., Andrews, S. F., Yassine, H. M., Wheatley, A. K., Fisher, B. E., Ambrozak, D. R., Creanga, A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0305-x · Cited by 301
Self-citationToward a Universal Influenza Virus Vaccine: Prospects and Challenges
Pica, N., & Palese, P. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-145115 · Cited by 284
Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281
A 2020 vision for vaccines against HIV, tuberculosis and malaria
Rappuoli, R., & Aderem, A. (2011) · Nature · doi:10.1038/nature10124 · Cited by 273
Nabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271
Self-citationStructural and genetic basis for development of broadly neutralizing influenza antibodies
Lingwood, D., McTamney, P. M., Yassine, H. M., Whittle, J. R. R., Guo, X., Boyington, J. C., Wei, C.-J., & Nabel, G. J. (2012) · Nature · doi:10.1038/nature11371 · Cited by 268
Self-citationViral vectors as vaccine platforms: deployment in sight
Rollier, C. S., Reyes-Sandoval, A., Cottingham, M. G., Ewer, K., & Hill, A. V. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.006 · Cited by 203
Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154
Ledgerwood, J. E., Zephir, K., Hu, Z., Wei, C.-J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit180 · Cited by 123
Self-citationNeutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine
Perche, F., Clemençon, R., Schulze, K., Ebensen, T., Guzmán, C. A., & Pichon, C. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.014 · Cited by 55
Metadata
- Authors
- Wei, C.-J., Boyington, J. C., McTamney, P. M., Kong, W.-P., Pearce, M. B., Xu, L., Andersen, H., Rao, S., Tumpey, T. M., Yang, Z.-Y., & Nabel, G. J.
- Venue
- Science
- Published
- 2010-08-27
- Volume
- 329
- Issue
- 5995
- Pages
- 1060-1064
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2009165647
- Cited by
- 337
- References
- 15
- FWCI
- 32.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.